Evidence map›Paper›PMID 31541082›Full record

ArticleCell death & disease2019

TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.

Janin Knop, Lisanne M Spilgies, Stefanie Rufli, Ramona Reinhart, Lazaros Vasilikos, Monica Yabal, Erika Owsley, Philipp J Jost, Rebecca A Marsh, Harald Wajant and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Monogenic disorders of the TNF signalling pathway.Nature reviews. Rheumatology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Regulation of apoptosis by ubiquitination in liver cancer.American journal of cancer research · 2023
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Janin KnopInstitute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
Lisanne M SpilgiesInstitute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
Stefanie RufliInstitute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
Ramona ReinhartInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Lazaros VasilikosInstitute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
Monica YabalIII. Medizinische Klink, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Erika OwsleyUC Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, USA.
Philipp J JostIII. Medizinische Klink, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-2454-0362
Rebecca A MarshUC Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, USA.
Harald WajantDivision of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Mark D RobinsonInstitute of Molecular Life Sciences and SIB Swiss Institute of Bioinformatics, University of Zürich, Zürich, Switzerland.
Thomas KaufmannInstitute of Pharmacology, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0001-9906-874X
W Wei-Lynn WongInstitute of Experimental Immunology, University of Zürich, Zürich, Switzerland. wong@immunology.uzh.ch.ORCID http://orcid.org/0000-0003-3155-1211
University of Zurich · CHCincinnati Children's Hospital Medical Center · USTUM Klinikum · DEUniversity of Bern · CHSIB Swiss Institute of Bioinformatics · CHUniversitätsklinikum Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pediatric immune deficiency X-linked proliferative disease-2 (XLP-2) is a unique disease, with patients presenting with either hemophagocytic lymphohistiocytosis (HLH) or intestinal bowel disease (IBD). Interestingly, XLP-2 patients display high levels of IL-18 in the serum even while in stable condition, presumably through spontaneous inflammasome activation. Recent data suggests that LPS stimulation can trigger inflammasome activation through a TNFR2/TNF/TNFR1 mediated loop in xiap

Identifiers

PMID31541082
PMCPMC6754467
OpenAlexW2973860554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.